weight loss amgen news

Amgen Stock Dives

Amgen Drug Delivers More Weight Loss Than Competitors

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Barron's on MSN · 1d

Amgen Stock Dives After Weight-Loss Drug Data. Here’s What to Know.

Amgen stock was dropping sharply Tuesday after releasing what looked like positive data from a Phase 2 study for its experimental monthly weight-loss shot MariTide.Overweight or obese patients on MariTide lost 20% of their body weight on average,

The Motley Fool on MSN · 1d

Why Amgen's Weight Loss Result Is a Win for Eli Lilly

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight management candidate. According to the giant drugmaker, treatment with an anti-obesity candidate called MariTide helped patients reduce their weight by up to 20% after 52 weeks.

What's Next for Amgen Obesity Drug After Investors Disappointed by Results

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

18h

Amgen's Phase 2 Results Were Not Bad, Don't Let Mr. Market Fool You

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

Amgen’s stock slides 7.8% after weight-loss drug data lags analyst expectations

Analysts were expecting the treatment to achieve an average weight loss of about 20% to 25% after one year of treatment, ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Amgen Stock Dives

Trending now